Critical aspects of clinical trial design for novel cell and gene therapies

Parkinson's Disease

Volumn , Issue , 2011, Pages

  Kefalopoulou, Zinovia ^a   Aviles Olmos, Iciar ^a   Foltynie, Thomas ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPAMINE F 18; DOPA; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; NEURTURIN; PRODRUG; VIRUS VECTOR;

BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; MOTOR PERFORMANCE; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

EID: 84855540055     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.4061/2011/804041     Document Type: Review

References (84)

1. Quinn N., Diagnosis and treatment of Parkinson's disease British Medical Journal 1995 310 6995 575 579
2. Bezard E., Brotchie J. M., Gross C. E., Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nature Reviews Neuroscience 2001 2 8 577 588 (Pubitemid 33679831)
3. Lang A. E., Obeso J. A., Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough Lancet Neurology 2004 3 5 309 316 (Pubitemid 38510202)
4. Garcia Ruiz P. J., Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study Movement Disorders 2008 23 8 1130 1136
5. Nyholm D., Nilsson Remahl A. I. M., Dizdar N., Constantinescu R., Holmberg B., Jansson R., Aquilonius S. M., Askmark H., Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology 2005 64 2 216 223
6. Krack P., Batir A., van Blercom N., Chabardes S., Fraix V., Ardouin C., Koudsie A., Limousin P. D., Benazzouz A., LeBas J. F., Benabid A. L., Pollak P., Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced parkinson's disease New England Journal of Medicine 2003 349 20 1925 1934 (Pubitemid 37409709)
7. Charles P. D., Gill C. E., Davis T. L., Konrad P. E., Benabid A. L., Is deep brain stimulation neuroprotective if applied early in the course of PD? Nature Clinical Practice Neurology 2008 4 8 424 426
8. Chaudhuri K. R., Schapira A. H., Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment The Lancet Neurology 2009 8 5 464 474
9. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C., Marsden C. D., Bjorklund A., Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease Science 1990 247 4942 574 577
10. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Kriek E., Qi J. X., Lone T., Zhang Y. B., Snyder J. A., Wells T. H., Ramig L. O., Thompson L., Mazziotta J. C., Huang S. C., Grafton S. T., Brooks D., Sawle G., Schroter G., Ansari A. A., Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease New England Journal of Medicine 1992 327 22 1549 1555
11. Lindvall O., Sawle G., Widner H., Rothwell J. C., Bjrklund A., Brooks D., Brundin P., Frackowiak R., Marsden C. D., Odin P., Rehncrona S., Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease Annals of Neurology 1994 35 2 172 180 (Pubitemid 24050152)
12. Freed C. R., Greene P. E., Breeze R. E., Tsai W. Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J. Q., Eidelberg D., Fahn S., Transplantation of embryonic dopamine neurons for severe Parkinson's disease New England Journal of Medicine 2001 344 10 710 719 (Pubitemid 32204988)
13. Olanow C. W., Goetz C. G., Kordower J. H., Stoessl A. J., Sossi V., Brin M. F., Shannon K. M., Nauert G. M., Perl D. P., Godbold J., Freeman T. B., A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease Annals of Neurology 2003 54 3 403 414 (Pubitemid 37072046)
14. Kordower J. H., Chu Y., Hauser R. A., Freeman T. B., Olanow C. W., Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease Nature Medicine 2008 14 5 504 506 (Pubitemid 351655212)
15. Li J. Y., Englund E., Holton J. L., Soulet D., Hagell P., Lees A. J., Lashley T., Quinn N. P., Rehncrona S., Bjrklund A., Widner H., Revesz T., Lindvall O., Brundin P., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation Nature Medicine 2008 14 5 501 503 (Pubitemid 351655211)
16. Li J. Y., Englund E., Widner H., Rehncrona S., Bjrklund A., Lindvall O., Brundin P., Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease Movement Disorders 2010 25 8 1091 1096
17. Yilong M., Tang C., Chaly T., Greene P., Breeze R., Fahn S., Freed C., Dhawan V., Eidelberg D., Dopamine cell implantation in Parkinson's disease: long-term clinical and18F-FDOPA PET outcomes Journal of Nuclear Medicine 2010 51 1 7 15
18. Piccini P., Pavese N., Hagell P., Reimer J., Bjrklund A., Oertel W. H., Quinn N. P., Brooks D. J., Lindvall O., Factors affecting the clinical outcome after neural transplantation in Parkinson's disease Brain 2005 128 12 2977 2986 (Pubitemid 41746650)
19. Winkler C., Kirik D., Bjrklund A., Cell transplantation in Parkinson's disease: how can we make it work? Trends in Neurosciences 2005 28 2 86 92 (Pubitemid 40178925)
20. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Bjrklund A., Brooks D. J., Marsden C. D., Oertel W. H., Quinn N. P., Rehncrona S., Lindvall O., Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease Brain 2000 123 7 1380 1390 (Pubitemid 30420938)
21. Politis M., Wu K., Loane C., Quinn N. P., Brooks D. J., Rehncrona S., Bjorklund A., Lindvall O., Piccini P., Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants Science Translational Medicine 2010 2 38
22. Freed W. J., Poltorak M., Becker J. B., Intracerebral adrenal medulla grafts: a review Experimental Neurology 1990 110 2 139 166
23. Goetz C. G., Olanow C. W., Koller W. C., Penn R. D., Cahill D., Morantz R., Stebbins G., Tanner C. M., Klawans H. L., Shannon K. M., Comella C. L., Witt T., Cox C., Waxman M., Gauger L., Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease New England Journal of Medicine 1989 320 6 337 341 (Pubitemid 19106868)
24. Schumacher J. M., Ellias S. A., Palmer E. P., Kott H. S., Dinsmore J., Dempsey P. K., Fischman A. J., Thomas C., Feldman R. G., Kassissieh S., Raineri R., Manhart C., Penney D., Fink J. S., Isacson O., Transplantation of embryonic porcine mesencephalic tissue in patients with PD Neurology 2000 54 5 1042 1050 (Pubitemid 30151843)
25. Lindvall O., Kokaia Z., Martinez-Serrano A., Stem cell therapy for human neurodegenerative disorders-How to make it work Nature Medicine 2004 10 supplement S42 S50
26. Kim J. H., Auerbach J. M., Rodrguez-Gmez J. A., Velasco I., Gavin D., Lumelsky N., Lee S. H., Nguyen J., Snchez-Pernaute R., Bankiewicz K., McKay R., Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease Nature 2002 418 6893 50 56 (Pubitemid 34742566)
27. Bjrklund L. M., Snchez-Pernaute R., Chung S., Andersson T., Chen I. Y. C., McNaught K. S. P., Brownell A. L., Jenkins B. G., Wahlestedt C., Kim K. S., Isacson O., Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model Proceedings of the National Academy of Sciences of the United States of America 2002 99 4 2344 2349 (Pubitemid 34169063)
28. O'Keeffe F. E., Scott S. A., Tyers P., O'Keeffe G. W., Dalley J. W., Zufferey R., Caldwell M. A., Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease Brain 2008 131 3 630 641 (Pubitemid 351294721)
29. Weiss M. L., Medicetty S., Bledsoe A. R., Rachakatla R. S., Choi M., Merchav S., Luo Y., Rao M. S., Velagaleti G., Troyer D., Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease Stem Cells 2006 24 3 781 792 (Pubitemid 44464783)
30. Bouchez G., Sensebé L., Vourc'h P., Garreau L., Bodard S., Rico A., Guilloteau D., Charbord P., Besnard J. C., Chalon S., Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease Neurochemistry International 2008 52 7 1332 1342
31. Wernig M., Zhao J. P., Pruszak J., Hedlund E., Fu D., Soldner F., Broccoli V., Constantine-Paton M., Isacson O., Jaenisch R., Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease Proceedings of the National Academy of Sciences of the United States of America 2008 105 15 5856 5861 (Pubitemid 351758462)
32. Vierbuchen T., Ostermeier A., Pang Z. P., Kokubu Y., Sdhof T. C., Wernig M., Direct conversion of fibroblasts to functional neurons by defined factors Nature 2010 463 7284 1035 1041
33. Redmond D. E., Bjugstad K. B., Teng Y. D., Ourednik V., Ourednik J., Wakeman D. R., Parsons X. H., Gonzalez R., Blanchard B. C., Kim S. U., Gu Z., Lipton S. A., Markakis E. A., Roth R. H., Elsworth J. D., Sladek J. R., Sidman R. L., Snyder E. Y., Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells Proceedings of the National Academy of Sciences of the United States of America 2007 104 29 12175 12180 (Pubitemid 47185649)
34. Berry A. L., Foltynie T., Gene therapy: a viable therapeutic strategy for Parkinson's disease? Journal of Neurology 2011 258 2 179 188
35. Caudle W. M., Colebrooke R. E., Emson P. C., Miller G. W., Altered vesicular dopamine storage in Parkinson's disease: a premature demise Trends in Neurosciences 2008 31 6 303 308
36. Chen L., Ding Y., Cagniard B., Van Laar A. D., Mortimer A., Chi W., Hastings T. G., Un J. K., Zhuang X., Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice Journal of Neuroscience 2008 28 2 425 433
37. Bjrklund A., Bjrklund T., Kirik D., Gene therapy for dopamine replacement in Parkinson's disease Science translational medicine 2009 1 2 2 ps2
38. Azzouz M., Martin-Rendon E., Barber R. D., Mitrophanous K. A., Carter E. E., Rohll J. B., Kingsman S. M., Kingsman A. J., Mazarakis N. D., Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease Journal of Neuroscience 2002 22 23 10302 10312 (Pubitemid 35416868)
39. Shen Y., Muramatsu S. I., Ikeguchi K., Fujimoto K. I., Fan D. S., Ogawa M., Mizukami H., Urabe M., Kume A., Nagatsu I., Urano F., Suzuki T., Ichinose H., Nagatsu T., Monahan J., Nakano I., Ozawa K., Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease Human Gene Therapy 2000 11 11 1509 1519 (Pubitemid 30670603)
40. Kirik D., Georgievska B., Burger C., Winkler C., Muzyczka N., Mandel R. J., Bjrklund A., Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer Proceedings of the National Academy of Sciences of the United States of America 2002 99 7 4708 4713 (Pubitemid 34286049)
41. Bankiewicz K. S., Forsayeth J., Eberling J. L., Sanchez-Pernaute R., Pivirotto P., Bringas J., Herscovitch P., Carson R. E., Eckelman W., Reutter B., Cunningham J., Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC Molecular Therapy 2006 14 4 564 570 (Pubitemid 44296090)
42. Jarraya B., Boulet S., Ralph G. S., Jan C., Bonvento G., Azzouz M., Miskin J. E., Shin M., Delzescaux T., Drouot X., Hérard A. S., Day D. M., Brouillet E., Kingsman S. M., Hantraye P., Mitrophanous K. A., Mazarakis N. D., Palfi S., Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia Science Translational Medicine 2009 1 2 2ra4
43. Eberling J. L., Jagust W. J., Christine C. W., Starr P., Larson P., Bankiewicz K. S., Aminoff M. J., Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 2008 70 21 1980 1983
44. Christine C. W., Starr P. A., Larson P. S., Eberling J. L., Jagust W. J., Hawkins R. A., Vanbrocklin H. F., Wright J. F., Bankiewicz K. S., Aminoff M. J., Safety and tolerability of putaminal AADC gene therapy for Parkinson disease Neurology 2009 73 20 1662 1669
45. Emborg M. E., Carbon M., Holden J. E., During M. J., Ma Y., Tang C., Moirano J., Fitzsimons H., Roitberg B. Z., Tuccar E., Roberts A., Kaplitt M. G., Eidelberg D., Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism Journal of Cerebral Blood Flow and Metabolism 2007 27 3 501 509
46. LeWitt P. A., Rezai A. R., Leehey M. A., Ojemann S. G., Flaherty A. W., Eskandar E. N., Kostyk S. K., Thomas K., Sarkar A., Siddiqui M. S., Tatter S. B., Schwalb J. M., Poston K. L., Henderson J. M., Kurlan R. M., Richard I. H., Van Meter L., Sapan C. V., During M. J., Kaplitt M. G., Feigin A., AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial The Lancet Neurology 2011 10 4 309 319
47. Lin L. F. H., Doherty D. H., Lile J. D., Bektesh S., Collins F., GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 1993 260 5111 1130 1132 (Pubitemid 23186789)
48. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., Hoffer B., Humpel C., Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo Experimental Neurology 1993 124 2 401 412 (Pubitemid 24041791)
49. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A., Functional recovery in parkinsonian monkeys treated with GDNF Nature 1996 380 6571 252 255 (Pubitemid 26090648)
50. Gill S. S., Patel N. K., Hotton G. R., O'Sullivan K., McCarter R., Bunnage M., Brooks D. J., Svendsen C. N., Heywood P., Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nature Medicine 2003 9 5 589 595 (Pubitemid 36597106)
51. Lang A. E., Gill S., Patel N. K., Lozano A., Nutt J. G., Penn R., Brooks D. J., Hotton G., Moro E., Heywood P., Brodsky M. A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V. G. F., Elias W. J., Laws E. R., Dhawan V., Stoessl A. J., Matcham J., Coffey R. J., Traub M., Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Annals of Neurology 2006 59 3 459 466 (Pubitemid 43358066)
52. Nutt J. G., Burchiel K. J., Comella C. L., Jankovic J., Lang A. E., Laws E. R., Lozano A. M., Penn R. D., Simpson R. K., Stacy M., Wooten G. F., Johnston L., Lopez J., Harrigan M., Marciano F. F., Carter J. H., Stone C., Trugman J., Rost-Ruffner E., O'Brien C., McVicker J. H., Davis T. L., Charles D., Allen G., Weiner W., Landy H. J., Bronstein J., Koller W., Pahwa R., Wilkinson S., Siemers E. R., Wojcieszek J. M., Witt T., Tuite P. J., Ebbitt B. J., Maxwell R., Cravets M., Hilt D., Klein M., Lee D. R., Schultz B., Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 2003 60 1 69 73 (Pubitemid 36070646)
53. Marks W. J., Bartus R. T., Siffert J., Davis C. S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., Bakay R., Watts R., Guthrie B., Jankovic J., Simpson R., Tagliati M., Alterman R., Stern M., Baltuch G., Starr P. A., Larson P. S., Ostrem J. L., Nutt J., Kieburtz K., Kordower J. H., Olanow C. W., Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial The Lancet Neurology 2010 9 12 1164 1172
54. Ceregene, Ceregene announces clinical data from phase 2 clinical trial of cere-120 for Parkinsons diseaselonger term follow-up indicates modest efficacy in primary and related endpoints. 2009, http://www.ceregene.com/press052709.asp
55. Kirik D., Winkler C., Bjrklund A., Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration Journal of Neuroscience 2001 21 8 2889 2896 (Pubitemid 32298229)
56. Hagell P., Cenci M. A., Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective Brain Research Bulletin 2005 68 1-2 4 15 (Pubitemid 41698871)
57. Marek K., Seibyl J., Beta-cit scans without evidemce of dopaminergic deficit (SWEDD) in the elldopa-cit and calm-cit study: long-term imaging assessment Neurology 2003 60 A293
58. Scherfler C., Schwarz J., Antonini A., Grosset D., Valldeoriola F., Marek K., Oertel W., Tolosa E., Lees A. J., Poewe W., Role of DAT-SPECT in the diagnostic work up of Parkinsonism Movement Disorders 2007 22 9 1229 1238 (Pubitemid 47325028)
59. Defer G. L., Widner H., Marié R. M., Rémy P., Levivier M., Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD) Movement Disorders 1999 14 4 572 584 (Pubitemid 30011449)
60. Goetz C. G., Fahn S., Martinez-Martin P., Poewe W., Sampaio C., Stebbins G. T., Stern M. B., Tilley B. C., Dodel R., Dubois B., Holloway R., Jankovic J., Kulisevsky J., Lang A. E., Lees A., Leurgans S., LeWitt P. A., Nyenhuis D., Olanow C. W., Rascol O., Schrag A., Teresi J. A., Van Hilten J. J., LaPelle N., Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan Movement Disorders 2007 22 1 41 47 (Pubitemid 46382671)
61. Nutt J. G., Carter J. H., Woodward W. R., Long-duration response to levodopa Neurology 1995 45 8 1613 1616
62. Muramatsu S. I., Fujimoto K. I., Kato S., Mizukami H., Asari S., Ikeguchi K., Kawakami T., Urabe M., Kume A., Sato T., Watanabe E., Ozawa K., Nakano I., A phase i study of aromatic l-amino acid decarboxylase gene therapy for parkinson's disease Molecular Therapy 2010 18 9 1731 1735
63. Hauser R. A., Deckers F., Lehert P., Parkinson's disease home diary: further validation amd implications for clinical trials Movement Disorders 2004 19 12 1409 1413 (Pubitemid 40104047)
64. Lyons K. E., Pahwa R., Electronic motor function diary for patients with Parkinson's disease: a feasibility study Parkinsonism and Related Disorders 2007 13 5 304 307 (Pubitemid 47002322)
65. Colosimo C., Martnez-Martn P., Fabbrini G., Hauser R. A., Merello M., Miyasaki J., Poewe W., Sampaio C., Rascol O., Stebbins G. T., Schrag A., Goetz C. G., Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations Movement Disorders 2010 25 9 1131 1142
66. Evans J. R., Mason S. L., Williams-Gray C. H., Foltynie T., Brayne C., Robbins T. W., Barker R. A., The natural history of treated Parkinson's disease in an incident, community based cohort Journal of Neurology, Neurosurgery and Psychiatry 2011 82 10 1112 1118
67. Den Oudsten B. L., Van Heck G. L., De Vries J., The suitability of patient-based measures in the field of Parkinson's disease: a systematic review Movement Disorders 2007 22 10 1390 1401 (Pubitemid 47287461)
68. Williams A., Gill S., Varma T., Jenkinson C., Quinn N., Mitchell R., Scott R., Ives N., Rick C., Daniels J., Patel S., Wheatley K., Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial The Lancet Neurology 2010 9 6 581 591
69. Brooks D. J., Neuroimaging in Parkinson's disease NeuroRx 2004 1 2 243 254 (Pubitemid 46613776)
70. Morrish P. K., Sawle G. V., Brooks D. J., An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease Brain 1996 119 2 585 591
71. Remy P., Samson Y., Hantraye P., Fontaine A., Defer G., Mangin J. F., Fenelon G., Geny C., Ricolfi F., Frouin V., N'Guyen J. P., Jeny R., Degos J. D., Peschanski M., Cesaro P., Clinical correlates of [18F]fluorodopa uptake in five grafted Parkinsonian patients Annals of Neurology 1995 38 4 580 588
72. Kordower J. H., Freeman T. B., Chen E. Y., Mufson E. J., Sanberg P. R., Hauser R. A., Snow B., Olanow C. W., Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease Movement Disorders 1998 13 3 383 393 (Pubitemid 28221487)
73. Kordower J. H., Freeman T. B., Snow B. J., Vingerhoets F. J. G., Mufson E. J., Sanberg P. R., Hauser R. A., Smith D. A., Nauert G. M., Perl D. P., Olanow C. W., Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease New England Journal of Medicine 1995 332 17 1118 1124
74. Cochen V., Ribeiro M. J., Nguyen J. P., Gurruchaga J. M., Villafane G., Loc'h C., Defer G., Samson Y., Peschanski M., Hantraye P., Cesaro P., Remy P., Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue Movement Disorders 2003 18 8 928 932 (Pubitemid 37021169)
75. Hagell P., Cenci M. A., Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective Brain Research Bulletin 2005 68 1-2 4 15 (Pubitemid 41698871)
76. Hagell P., Piccini P., Bjrklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W. H., Quinn N., Brooks D. J., Lindvall O., Dyskinesias following neural transplantation in Parkinson's disease Nature Neuroscience 2002 5 7 627 628 (Pubitemid 34742975)
77. Politis M., Oertel W. H., Wu K., Quinn N. P., Pogarell O., Brooks D. J., Bjorklund A., Lindvall O., Piccini P., Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio Movement Disorders 2011 26 11 1997 2003
78. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D. J., Piccini P., Staging of serotonergic dysfunction in Parkinson's Disease: an in vivo 11C-DASB PET study Neurobiology of Disease 2010 40 1 216 221
79. Chow S. C., Shao J., Wang H., Sample Size Calculation in Clinical Research 2008 2nd New York, NY, USA Chapman Hall/CRC
80. Albin R. L., Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls Journal of Medical Ethics 2002 28 5 322 325
81. Shetty N., Friedman J. H., Kieburtz K., Marshall F. J., Oakes D., The placebo response in Parkinson's disease Clinical Neuropharmacology 1999 22 4 207 212 (Pubitemid 30004136)
82. Goetz C. G., Wuu J., McDermott M. P., Adler C. H., Fahn S., Freed C. R., Hauser R. A., Olanow W. C., Shoulson I., Tandon P. K., Kieburtz K., Leurgans S., Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions Movement Disorders 2008 23 5 690 699
83. Dickson D. W., Fujishiro H., Orr C., DelleDonne A., Josephs K. A., Frigerio R., Burnett M., Parisi J. E., Klos K. J., Ahlskog J. E., Neuropathology of non-motor features of Parkinson disease Parkinsonism and Related Disorders 2009 15 3, supplement 3 S1 S5
84. Ggel S. Gubernator M. Minger S.L., Progress and prospects: stem cells and neurological diseases, Gene Therapy, 2011, 18, 1, 1-6